Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Canopy Growth Corp T.WEED

Alternate Symbol(s):  CGC | T.WEED.DB

Canopy Growth Corporation is a cannabis company. It delivers innovative products with a focus on premium and mainstream cannabis brands, including Doja, 7ACRES, Tweed, and Deep Space, in addition to category-defining vaporizer technology made in Germany by Storz & Bickel. The principal activities of the Company are the production, distribution and sale of a diverse range of cannabis and cannabinoid-based products for both adult-use and medical purposes under a portfolio of distinct brands in Canada. Its Canada cannabis segment includes the production, distribution, and sale of a range of cannabis, hemp, and cannabis related products in Canada. International markets cannabis segment includes the production, distribution, and sale of a range of cannabis and hemp products internationally. Storz & Bickel segment includes the production, distribution, and sale of vaporizers. This Works segment includes the production, distribution and sale of beauty, skincare, wellness and sleep products.


TSX:WEED - Post by User

Bullboard Posts
Post by Bobthebuilddron Jan 08, 2017 12:37am
285 Views
Post# 25679991

2017 Q1 revenue

2017 Q1 revenueSo there first reporting period, they had a revenue of 7 million. MT in the same period had a revenue of 4.1 million. For a combined revenue of 11.1 million. Both companies reported huge increases in registered patients. Which leads me to believe the following. If in Q2, they add 10% new clients per month, which is the current industry average. And not far a huge expectation. Last I saw MT had 12,000 clients and Canopy was in the 17000 client range. If the trend with medical prescriptions continues, There Q1 2018 report should have the at a revenue of roughly 25million quarterly. Although I wouldn't be surprised if they were well above 30 million quarterly. This is based on medical and not recreational. Although, this is amazing. Recreational is what we all want. Some quick numbers. If canopy can achieve a 1.5billion dollar revenue. Which isn't that hard for a recreational market. That is supplying less theb 20%. They would be giving approximately $4.20 per share as a price. The would put the stock price between $42 - $130 depending on how the market values the leading company. Now let's do a little dividend action. Although they have no current plans, by 2020 they will be in full swing and looking to reward investors. If canopy is making 1.5 billion per year in revenue, there profit margin is roughly 40%. So that's 600 million. Half that profit will be used for expansion/acquisition. While the remaining 300 million could be used for quarterly dividends. Although I'm not really sure 100% on a number right now. I believe it will be around 40 cents per share, maybe more who knows till it happens. Which leads be to believe that the share price then will be closer to $80 to $120 since there is such a high margin for profit. My advice. Buy at whatever the price is Monday or next month. Doesn't really matter at all. The medium to long term profits will make millionaires. Cheers
Bullboard Posts